Diarmuid Moran to Protein Kinase Inhibitors
This is a "connection" page, showing publications Diarmuid Moran has written about Protein Kinase Inhibitors.
Connection Strength
0.276
-
A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations. Clin Cancer Res. 2017 Dec 15; 23(24):7467-7473.
Score: 0.108
-
A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity. Toxicol Sci. 2015 Jan; 143(1):147-55.
Score: 0.088
-
Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013 Oct 01; 272(1):245-55.
Score: 0.080